Insilico Medicine disclosed a first‑in‑class AI‑designed PROTAC degrader targeting PKMYT1 (D16‑M1P2) and published preclinical efficacy in Nature Communications. The bifunctional molecule links a novel PKMYT1 ligand to a cereblon binder and showed potency in CCNE1‑amplified and FBXW7‑mutant tumor models, suggesting biomarker‑driven indications such as subsets of breast and cholangiocarcinoma. Researchers highlighted that AI generation accelerated the design cycle and produced a degrader with consistent preclinical activity across cell lines and xenografts. Insilico framed the program as a precision‑medicine approach that would focus clinical translation on genomically defined patient populations. Clarification: A PROTAC (proteolysis‑targeting chimera) recruits a target protein to the cell’s ubiquitin‑proteasome machinery to induce degradation rather than just inhibition.